Join the 'Parkinson's Disease' group to help and get support from people like you.

Parkinson's Disease Blog

Related terms: Parkinson's

Brisk Walking May Help Curb Parkinson's Symptoms

Posted 3 Jul 2014 by

WEDNESDAY, July 2, 2014 – People with Parkinson's disease who regularly walk for exercise may significantly improve their physical and mental function, a new study finds. "The benefits of exercise that apply to a normal, healthy person are even greater in Parkinson's disease because it also affects the symptoms of the disease. A person with Parkinson's will get all the benefits that a normal, healthy person does, plus it will modify the symptoms of their disease," said Dr. Daniel Corcos, a professor of physical therapy and human movement sciences at Northwestern University in Chicago. Corcos was not involved in the new study. Parkinson's is a motor system disorder that impairs a person's ability to control their muscle movements. The new study, published online July 2 in the journal Neurology, involved 60 Parkinson's disease patients between the ages of 50 and 80. All were in the early ... Read more

Related support groups: Parkinson's Disease

MRI Technique May Help Detect Parkinson's Earlier

Posted 12 Jun 2014 by

THURSDAY, June 12, 2014 – A simple and quick MRI technique might aid in early detection of Parkinson's disease, British researchers report. The new MRI approach can detect with 85 percent accuracy people who have early stage Parkinson's disease, according to findings published online June 11 in the journal Neurology. That's important because the early symptoms of Parkinson's are subtle, which makes an accurate early stage diagnosis very difficult, the researchers said. This new test, which focuses on scans of a part of the brain known as the basal ganglia, could improve the lives of countless patients with Parkinson's, said senior author Clare Mackay, a senior research fellow with the Oxford Parkinson's Disease Center at Oxford University. "By the time symptoms of Parkinson's are obvious, a lot of damage has already taken place in the brain," Mackay said. "To reduce the impact of ... Read more

Related support groups: Parkinson's Disease, Diagnosis and Investigation, CNS Magnetic Resonance Imaging

FDA Approves Expanded Label for Azilect for Treatment Across All Stages of Parkinson’s Disease

Posted 11 Jun 2014 by

JERUSALEM--(BUSINESS WIRE)--Jun. 9, 2014-- Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that Azilect can be used alone or in combination with other Parkinson’s disease (PD) medications. The approval reinforces the growing clinical evidence demonstrating the benefit of Azilect across all stages of PD. “The FDA approval of the expanded label for Azilect will be a welcome addition in the treatment of PD,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “Teva continues its commitment to those living with PD and to research in areas of neurodegenerative diseases to develop solutio ... Read more

Related support groups: Parkinson's Disease, Azilect, Rasagiline

Levodopa May Beat Newer Meds for Long-Term Parkinson's Care: Study

Posted 11 Jun 2014 by

WEDNESDAY, June 11, 2014 – When it comes to which drug works best for patients with newly diagnosed Parkinson's disease, older may still be better, a new study finds. Research published June 10 in The Lancet finds that the dopamine drug levodopa still outperforms newer medications for the long-term care of people newly diagnosed with Parkinson's. "This study lays to rest lingering questions among both people with Parkinson's disease and their doctors about which drug is most beneficial when first beginning treatment for the disease," said James Beck, vice president of scientific affairs at the Parkinson's Disease Foundation (PDF). In the largest-ever trial of Parkinson's disease treatment, levodopa offered patients better mobility and a higher quality of life than the two main alternatives – drugs called dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors. The study ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Stalevo, Carbidopa/Levodopa, Sinemet CR, Stalevo 100, Parcopa, Stalevo 200, Stalevo 150, Atamet, Larodopa, Dopar, Stalevo 50, Carbidopa/Entacapone/Levodopa

Study Supports Durability of Parkinson's Treatment

Posted 5 Jun 2014 by

THURSDAY, June 5, 2014 – Therapeutic, transplanted brain cells producing the brain chemical dopamine remain viable in Parkinson's disease patients for many years, a new study reveals. The findings "suggest that transplanted dopamine neurons can remain healthy and functional for decades," study co-author Ole Isacson, of Harvard University and McLean Hospital in Boston, said in a news release from the journal Cell Reports. The study was published in the journal on June 5. As explained by the study authors, the tremors and other symptoms experienced by Parkinson's disease patients are caused by the loss of dopamine-producing neurons (brain cells). Healthy dopamine-producing neurons can be transplanted into patients' brains, but there were questions about how long the transplanted cells would remain healthy. This study included five Parkinson's patients who had received transplants of ... Read more

Related support groups: Parkinson's Disease

Vitamin D Levels Linked to Parkinson's Symptoms

Posted 22 Jan 2014 by

WEDNESDAY, Jan. 22, 2014 – Higher vitamin D levels are associated with better thinking and mood in people with Parkinson's disease, a new study suggests. The finding may lead to new ways to delay or prevent the onset of thinking problems and depression in people with the progressive neurodegenerative disease, the researchers said. Their analysis of nearly 300 Parkinson's disease patients revealed that higher blood levels of vitamin D – the "sunshine vitamin" – were associated with less severe physical symptoms, better thinking abilities and lower risk of depression. This link was especially strong in patients without dementia, according to the study in the current issue of the Journal of Parkinson's Disease. "About 30 percent of persons with [Parkinson's disease] suffer from cognitive impairment and dementia, and dementia is associated with nursing home placement and shortened life ... Read more

Related support groups: Parkinson's Disease, Vitamin D, Vitamin D3, D3, Cholecalciferol, Ergocalciferol, Drisdol, Replesta, Calciferol, Delta D3, Maximum D3, D3-5, D400, D2000, D 1000 IU, Decara, D3-50, Calcidol

Nutritional Supplement May Benefit Parkinson's Patients

Posted 23 Dec 2013 by

MONDAY, Dec. 23, 2013 – A common nutritional supplement called inosine safely boosts levels of an antioxidant thought to help people with Parkinson's disease, a small new study says. Inosine is a forerunner of the antioxidant known as urate. Inosine is naturally converted by the body into urate, but urate taken by mouth breaks down in the digestive system. "Higher urate levels are associated with a lower risk of developing Parkinson's disease, and in Parkinson's patients, may confer a slower rate of disease worsening," explained Dr. Andrew Feigin, a neurologist at the Cushing Neuroscience Institute's Movement Disorders Center in Manhasset, N.Y. He was not connected to the new study. The study included 75 people who were newly diagnosed with Parkinson's and had low levels of urate. Those who received doses of inosine meant to boost urate levels showed a rise in levels of the antioxidant ... Read more

Related support groups: Parkinson's Disease, Dietary Supplementation

Could Deep Brain Stimulation Make Parkinson's Patients Better Drivers?

Posted 18 Dec 2013 by

WEDNESDAY, Dec. 18, 2013 – Deep brain stimulation might help improve the driving ability of people with Parkinson's disease, a new German study suggests. A deep brain stimulator is an implanted device that sends electrical impulses to the brain. With patients who have epilepsy, the stimulator is believed to lower the risk of seizures, the researchers said. A driving simulator tested the abilities of 23 Parkinson's patients with a deep brain stimulator, 21 patients without the device and a control group of 21 people without Parkinson's. The patients with brain stimulators were tested three times: once with the device on, once with the device off and once with the stimulator off after they took the Parkinson's drug levodopa. The Parkinson's patients without stimulators performed worse in every driving category except one. The patients with stimulators did not perform significantly worse ... Read more

Related support groups: Parkinson's Disease

Exercise Seems to Ease Parkinson's-Related Depression

Posted 13 Dec 2013 by

THURSDAY, Dec. 12, 2013 – A long-term exercise program may help ease depression in people with Parkinson's disease, according to a new, small study. Researchers looked at 31 Parkinson's patients who were randomly assigned to an "early start" group that did an exercise program for 48 weeks or a "late start" group that worked out for 24 weeks. The program included three one-hour cardiovascular and resistance training workouts a week. Depression symptoms improved much more among the patients in the 48-week group than among those in the 24-week group. This is important because mood is often more debilitating than movement problems for Parkinson's patients, said study leader Dr. Ariane Park, a movement disorder neurologist at Ohio State University's Wexner Medical Center. The study was published online recently in the journal Parkinsonism & Related Disorders. More than half of Parkinson's ... Read more

Related support groups: Depression, Parkinson's Disease

Study Sheds Light on Link Between Pesticides, Parkinson's

Posted 27 Nov 2013 by

WEDNESDAY, Nov. 27, 2013 – Researchers have identified a genetic mutation that increases the risk of Parkinson's disease linked to pesticides. The gene mutation causes nerve cells that produce a substance called "dopamine" to lose their protection from pesticide damage. The body uses dopamine to send messages to the part of the brain that controls movement and coordination. Parkinson's disease – which causes movement problems such as stiffness, tremors and slurred speech – occurs when nerve cells in the brain don't produce enough dopamine. The study is the first "to show that a genetic mutation combined with exposure to pesticides creates a 'double-hit' scenario," by disabling specific pathways, which then leads to nerve-cell death, study senior author Dr. Stuart Lipton, professor and director of Sanford-Burnham Medical Research Institute's Center for Neuroscience, Aging, and Stem ... Read more

Related support groups: Parkinson's Disease

New Drug Shows Early Promise in Treating Parkinson's Psychosis

Posted 1 Nov 2013 by

THURSDAY, Oct. 31 – Many people living with Parkinson's disease suffer from hallucinations and delusions, but an experimental drug might offer some relief without debilitating side effects. The drug – pimavanserin – appears to significantly relieve these troubling symptoms, according to the results of a phase 3 trial to test its effectiveness. Such symptoms affect as many as half of the estimated 7 million to 10 million Parkinson's patients around the world, according to study background information. Currently, patients are treated with antipsychotic drugs such as clozapine and quetiapine, which worsen Parkinson's motor symptoms, hasten mental decline, increase the risk of stroke and can be life-threatening, authors of the new study said. Their study was published in the Nov. 1 online issue of The Lancet and funded by Acadia Pharmaceuticals, the makers of pimavanserin. "There are no ... Read more

Related support groups: Parkinson's Disease, Drug Psychosis, Parkinsonism

Parkinson's Patients at Genetic Risk for Dementia Might Be Identified Sooner

Posted 20 Sep 2013 by

FRIDAY, Sept. 20 – Blood tests might be able to help identify Parkinson's disease patients with the greatest risk of developing dementia, a new study suggests. A genetic mutation called GBA leads to early onset of Parkinson's and severe mental decline in about 4 percent to 7 percent of Parkinson's patients. It also alters the way the body metabolizes certain kinds of fats. Mayo Clinic researchers found that Parkinson's patients who do not have this genetic mutation have higher levels of these fats in their blood. They also discovered that Parkinson's patients with high levels of these fats in their blood are more likely to have mental impairment and dementia, according to the study, which was published online Sept. 18 in the journal PLoS One. Mental impairment is a frequent symptom in Parkinson's disease and can be even more debilitating for patients and challenging for their ... Read more

Related support groups: Parkinson's Disease, Dementia

Genetic Syndrome May Have Links to Parkinson's Disease

Posted 9 Sep 2013 by

MONDAY, Sept. 9 – A genetic deletion may be linked to some cases of early onset Parkinson's disease, researchers say. The investigators found that people aged 35 to 64 who were missing DNA on a specific part of chromosome 22 were about 90 times more likely to develop Parkinson's than people from the same age group in the general population. People with this inherited genetic condition – called 22q11.2 deletion syndrome – have about 50 genes missing on chromosome 22. The condition occurs in about one in 2,000 to 4,000 people, and those with this genetic deletion may have birth defects (including heart defects), learning or speech difficulties, anxiety disorders, or schizophrenia. Previously reported cases of patients with 22q11.2 deletion syndrome and Parkinson's disease symptoms have indicated that there may be a link between the two conditions, according to the researchers from the ... Read more

Related support groups: Parkinson's Disease

Spinal Fluid Test May Aid Early Detection of Parkinson's Disease

Posted 27 Aug 2013 by

TUESDAY, Aug. 27 – Testing for certain proteins in spinal fluid may help doctors diagnose Parkinson's disease earlier and determine how fast the movement disorder is likely to advance, according to new research. The team from the Perelman School of Medicine at the University of Pennsylvania said their discovery of these protein "biomarkers" might also aid in the development of new Parkinson's treatments. "Biomarkers for Parkinson's disease such as these could help us diagnose patients earlier," study senior author Leslie Shaw, a professor of pathology and laboratory medicine at Penn Medicine, said in a university news release. Shaw and Dr. John Trojanowski are co-leaders in the bioanalytics core for the Parkinson's Progression Markers Initiative (PPMI), an international study sponsored by The Michael J. Fox Foundation for Parkinson's. They led a team that collected spinal fluid from ... Read more

Related support groups: Parkinson's Disease, Diagnosis and Investigation

FDA Medwatch Alert: Benztropine Mesylate Injection (Nexus Pharmaceuticals): Recall - Visible Particulate Matter

Posted 5 Aug 2013 by

ISSUE: Nexus Pharmaceuticals Inc. is recalling two lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the presence of visible particulate matter in the vials. The product is manufactured by Allergy Laboratories, Inc. and was distributed by Nexus Pharmaceuticals Inc. Affected product includes Lot Numbers 030712, 112911 The administration of particulate, if present in a parenteral drug, poses a safety risk to patients. Sequelae of thromboembolism, some life-threatening (such as pulmonary emboli), may occur. There is also risk for particulates causing phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli. Patients with preexisting condition of trauma or other medical condition that adversely affects the microvascular blood supply are at an increased risk. ... Read more

Related support groups: Parkinson's Disease, Cogentin, Benztropine, Extrapyramidal Reaction, Parkinsonian Tremor, Parkinsonism

Page 1 2 3 4 5 6 7 8 Next

Ask a Question

Further Information

Related Condition Support Groups

Parkinsonian Tremor, Parkinsonism, Central Nervous System Disorders

Related Drug Support Groups

Mirapex, Requip, Sinemet, ropinirole, benztropine, creatine, Cogentin, Exelon, Azilect, view more... pramipexole, belladonna, levodopa, bromocriptine, selegiline, amantadine, Neupro, Parlodel, Artane, trihexyphenidyl, Stalevo, Sinemet CR, Requip XL, carbidopa/levodopa, Comtan, Stalevo 100, rasagiline, entacapone, rivastigmine, Eldepryl, procyclidine, Symmetrel, rotigotine, Apokyn, Parcopa, pergolide, Stalevo 150, Trihexane, Belladonna Tincture, Uprima, Requip Starter Kit, Repreve, Mirapex ER, Tasmar, Akineton, Stalevo 200, Permax, apomorphine, ReQuip Starter Pack, Trihexy, APO-Go, APO-Go Pen, Stalevo 50, Kemadrin, Zelapar, Dopar, tolcapone, carbidopa/entacapone/levodopa, biperiden, Larodopa, Akineton HCl, Selgene, Atamet, Jumex, Atapryl, Carbex, ReQuip Follow on Pack